Skip to main content

Table 3 Comparing different ARV exposure groups and adverse birth outcomes (ABOs)

From: Option B+ for prevention of vertical HIV transmission has no influence on adverse birth outcomes in a cross-sectional cohort in Western Uganda

Variables Still-birth N (%) a OR CI 95% P valueb Preterm Delivery
N (%)c
OR CI
95%
P
valueb
Small for gest. age
N (%)d
OR CI 95% P valueb Any ABO
N (%)
OR CI 95% P valueb
Drug exposure 25     112     44     158    
HIV negative 20 (6.6) 1    85 (28.2) 1    33 (11.3) 1    119 (39.7) 1   
ART pre-conception 3 (7.9) 1.21 0.34–4.28 0.73e 11 (28.9) 1.04 0.49–2.18 0.93 3 (8.3) 0.71 0.21–2.46 0.78e 13 (35.1) 0.82 0.4–1.68 0.59
Option B+ 2 (3.4) 0.5 0.11–2.18 0.55e 16 (27.6) 0.97 0.52–1.81 0.92 8 (13.8) 1.3 0.55–2.88 0.59 26 (44.1) 1.2 0.68–2.11 0.53
ARV regimens 5     27     11     39    
ART pre-conception 3 (7.9) 1    11 (28.9) 1    3 (8.3) 1    13 (35.1) 1   
Option B+ 2 (3.4) 0.41 0.07–2.57 0.38e 16 (27.6) 0.94 0.38–2.32 0.89 8 (13.8) 1.76 0.44–7.12 0.52e 26 (44.1) 1.46 0.62–3.4 0.39
Drug initiationf 5     27     11     39    
ARV exposure after GW 14 2 (4.3) 1    12 (26.7) 1    6 (13.3) 1    20 (43.5) 1   
ARV exposure before GW 14 3 (6.0) 1.4 0.22–8.81 1e 15 (30.0) 1.18 0.48–2.89 0.72 5 (10.4) 0.76 0.21–2.67 0.66 19 (38.8) 0,82 0.36–1.87 0.64
Any ARV intake ≥90 days prior delivery 5 (6.2) 1    21 (26.3) 1    8 (10.3) 1    8 (53.5) 1   
Any ARV intake <90 days prior delivery 0 (0) 0.84 0.76–0.92 1e 6 (40.0) 1.87 0.6–5.9 0.35e 3 (20.0) 0.46 0.11–1.97 0.38e 31 (38.8) 0.55 0.18–1.68 0.29
Exposure time 25     112     44     158    
HIV negative 20 (6.6) 1    85 (28.2) 1    33 (11.3) 1    119 (39.7) 1   
ARV exposure before GW 14 3 (6.0) 0.9 0.26–3.15 1e 15 (30.0) 1.09 0.57–2.1 0.8 5 (10.4) 0.91 0.34–2.47 0.86 19 (38.8) 0.96 0.52-1.79 0.91
Any ARV intake ≥90 days prior delivery 5 (5.2) 0.78 0.28–2.12 0.62 27 (28.4) 1.01 0.61–1.68 0.97 11 (11.8) 1.05 0.51–2.18 0.89 39 (41.1) 1.06 0.66–1.69 0.81
PMTCT intake prior delivery in days, Median (range) 135
(126–144)
   0.86g 113,5
(14–278)
   0.6g 125
(19–232)
   0.73g 129 (14–278)    0.71g
  1. aTotal SB: 26; number excludes one woman who was on Option A at the time of delivery
  2. ball data are bivariate, Pearson’s X2 asymptotic two- sided p- value, apart from where indicated differently
  3. cTotal PTD: 116; number excludes three women on Option A and one HIV positive woman without ARV treatment
  4. dTotal SGA: 47; number excludes two women on Option A and one woman with undocumented PMTCT regimen
  5. eBivariate Fisher’s Exact test two- sided p- value
  6. fOne woman on Option B+ excluded due to missing drug initiation date
  7. gMann–Whitney-U Test